Cogent Biosciences, Inc. (COGT)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Wall Street Analysts Believe Cogent Biosciences (COGT) Could Rally 224.37%: Here's is How to Trade
The consensus price target hints at a 224.4% upside potential for Cogent Biosciences (COGT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Is Cogent Biosciences (COGT) Stock a Solid Choice Right Now?
Cogent Biosciences (COGT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Is Cogent Biosciences (COGT) Outperforming Other Medical Stocks This Year?
Here is how Cogent Biosciences, Inc. (COGT) and Cardiol Therapeutics Inc. (CRDL) have performed compared to their sector so far this year.
Cogent Biosciences: Buy The Pullback For Bezuclastinib's 2025 SM And GIST Data
Bezuclastinib is COGT's main value driver, currently undergoing 3 late-stage trials for SM and GIST. COGT's SUMMIT Part 2 for nonAdvSM will give us decisive data in July 2025, which I consider its main catalyst this year. Bezuclastinib could target an aggregate TAM of up to $2.5 billion across NonAdvSM, AdvSM, and GIST, which dwarves its current market cap.
Why Is Cogent Biosciences Stock Trading Higher On Monday?
On Sunday, Cogent Biosciences, Inc. COGT revealed updated clinical results from the Open Label Extension (OLE) portion of the SUMMIT trial of bezuclastinib in patients with non-advanced systemic mastocytosis.
Cogent (COGT) Up on SUMMIT Study Update Post Positive FDA Meeting
Cogent (COGT) announces a positive FDA meeting and alignment on MS2D2, a novel patient-reported outcome measure for the SUMMIT study. The company's shares rise on the news.
